Vallourec Wins a New Major Line Pipe Contract for Brazil's Buzios Offshore Field
Press release
VALLOUREC WINS A NEW MAJOR LINE PIPE CONTRACT FOR BRAZIL'S BUZIOS OFFSHORE FIELD
Meudon (France), April 22, 2025 – Vallourec, a world leader in premium seamless tubular solutions, announces today that it has secured a major contract with Allseas to supply line pipes for Búzios 10 offshore project located at the Búzios field, operated by Petrobras. This contract represents nearly 18,000 tons of subsea seamless premium carbon steel line pipes, for the risers and flowlines. The contract includes an optional scope of almost 5,000 tons.
Located off the coast of Rio de Janeiro, Búzios is one of the world's largest deepwater fields. This field represents a significant part of the Brazilian oil company's operations. The field's production is expected to substantially increase as five additional units are set to commence operations by 2028.
The contract also includes Vallourec's Pipe Navigator solution, a centralized digital portal that offers instant access to up-to-date contractual documentation, data and analysis covering every aspect of its line pipe projects. The entire production will be carried out at our cutting-edge facility in Jeceaba (Minas Gerais, Brazil) to ensure high local content and a reduced carbon footprint.
Philippe Guillemot, Group's Chairman and CEO declared: 'This contract reinforces our strategic positioning in Brazil, one of our key markets for complex offshore projects. It also serves as legacy to our ability to deliver premium tubular solutions, fully manufactured in Brazil. This contract also validates the investment strategy implemented over the past three years to enhance our industrial performance and meet the most demanding requirements of our customers.'
About Vallourec
Vallourec is a world leader in premium tubular solutions for the energy markets and for demanding industrial applications such as oil & gas wells in harsh environments, new generation power plants, challenging architectural projects, and high-performance mechanical equipment. Vallourec's pioneering spirit and cutting-edge R&D open new technological frontiers. With close to 13,000 dedicated and passionate employees in more than 20 countries, Vallourec works hand-in-hand with its customers to offer more than just tubes: Vallourec delivers innovative, safe, competitive and smart tubular solutions, to make every project possible.
Listed on Euronext in Paris (ISIN code: FR0013506730, Ticker VK), Vallourec is part of the CAC Mid 60, SBF 120 and Next 150 indices and is eligible for Deferred Settlement Service.
In the United States, Vallourec has established a sponsored Level 1 American Depositary Receipt (ADR) program (ISIN code: US92023R4074, Ticker: VLOWY). Parity between ADR and a Vallourec ordinary share has been set at 5:1.
For further information, please contact:
Investor relations:Connor LynaghTel: +1 (713) 409-7842connor.lynagh@vallourec.com
Individual shareholders:Toll Free number (From France): 0 805 65 10 10actionnaires@vallourec.com
Press relations: TaddeoRomain GrièreTel: +33 (0)7 86 53 17 29romain.griere@taddeo.fr
Nicolas EscoulanTel: +33 (0)6 42 19 14 74nicolas.escoulan@taddeo.fr
Attachment
Vallourec_Press Release_Buzios
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
HSBC upgrades Dr Reddy's on weight loss drug semaglutide-driven earnings rebound
-- HSBC upgraded Dr Reddy's Laboratories to Buy from Hold and raised its target price to INR 1445, citing expectations that sales of semaglutide, a generic version of Novo Nordisk's blockbuster weight-loss and diabetes drug, will help drive a recovery in earnings growth from fiscal new target for the U.S.-listed ADR is $16.90, up from $14.44. The brokerage forecasts Dr Reddy's semaglutide revenues at $280 million in 2027, contributing about 18% of the company's earnings per share, with the bulk of those sales expected to come from the Canadian market. In a bullish case, HSBC sees potential sales reaching $500 million. Dr Reddy is preparing for a post-gRevlimid era. The company is expected to lose a major chunk of its earnings from generic Revlimid after January 2026, with investors concerns about what will fuel growth after that. HSBC said semaglutide, along with other efforts in consumer health and biologics, offers a promising path forward. While a court order in India has restricted semaglutide exports until the original brand's local patent expires in March 2026, HSBC believes Dr Reddy's will be among the first to launch in markets such as Canada, Brazil, and India shortly thereafter. The note highlighted tight supply and strong demand for semaglutide in these markets, which could limit price erosion, a typical challenge for generic drugs. HSBC now assumes an early FY27 launch across key geographies instead of only Canada in late FY26. The firm cut FY26 EPS estimates by 5.1% due to declining Revlimid sales but raised FY27 and FY28 forecasts by 12–13% on semaglutide-led growth. Related articles HSBC upgrades Dr Reddy's on weight loss drug semaglutide-driven earnings rebound Morgan Stanley starts Parker-Hannifin at Equal-weight rating Huawei struggles to break Nvidia's AI chip grip in China, says The Information Sign in to access your portfolio
Yahoo
2 hours ago
- Yahoo
Brazil's Lula urges Macron to seal Mercosur trade deal
Brazil's President Luiz Inacio Lula da Silva urged his French counterpart Emmanuel Macron on Thursday to "finalise" an EU trade deal with four South American countries, in a visit that underscored key policy differences between the two allies. France has opposed ratifying the so-called Mercosur agreement, a trade deal between the European Union and four South American nations including Brazil, over fears a flow of lower-cost agricultural goods would outcompete Europe's farmers. "Open your heart a little to this opportunity to finalise this agreement with our dear Mercosur," Lula said during a state visit to Paris. "This agreement would be the strongest response our regions could offer in the face of the uncertainty caused by the return of unilateralism and tariff protectionism," he added, referring to sweeping tariffs imposed or threatened by US President Donald Trump. Trump, who argues that his tariffs will bring manufacturing jobs back to the United States, has hit the EU with multiple waves of levies. For his part, Macron reiterated his concerns about the deal's impact on French farmers, citing differences in environmental regulations between the EU and Mercosur countries. "I don't know how to explain to my farmers that, at a time when I am asking them to comply with more standards, I am opening up my market on a massive scale to people who do not comply at all," Macron said. "Because what will happen? It won't be better for the climate, but we will completely destroy our agriculture," he added. "That is why I said earlier we must improve this deal." Germany, Spain, Portugal and others have welcomed the accord with Mercosur bloc members Argentina, Brazil, Paraguay and Uruguay, but France has said from the start it is not acceptable in its current form. To be approved, the deal must receive the backing of at least 15 of the 27 EU states, representing a minimum of 65 percent of the population. -'Premeditated genocide'- This marks the first state visit to France by a Brazilian president since 2012, and comes just months ahead of the United Nations' COP30 climate conference, which Brazil will host in November. While both Macron and Lula praised the strong ties between France and Brazil, Thursday's press conference highlighted diverging views over the war in Gaza and Russia's invasion of Ukraine. Lula accused Israel of carrying out "premeditated genocide" in the Palestinian territory of Gaza. "(It is) a premeditated genocide from a far-right government that is waging a war against the interests of its own people," he said at the joint press conference with Macron. While Lula has previously used the term "genocide", Macron has refused to, saying last month it was not for a "political leader to use to term but up to historians to do so when the time comes". France is due later this month to co-host with Saudi Arabia a United Nations conference in New York on a two-state solution to the conflict between Israel and the Palestinians. Macron said that he expected the conference would take steps "towards recognising Palestine", without being more specific. Brazil recognised a Palestinian state in 2010. -'Aggressor, victim'- On the war in Ukraine, Macron stressed that Kyiv and Moscow should not be treated as equals, in contrast to Brazil's proclaimed neutral stance on the conflict. "There is an aggressor, which is Russia. There is a victim, which is Ukraine. We all want peace, but we cannot treat the two belligerents equally," said Macron, stressing that Brazil had "a very important role to play" in finding a solution to the conflict. Lula said he hoped to reinforce Brazil's ties with Russia during his May 9 trip to Moscow, where he was marking 80 years since the defeat of Nazi Germany alongside some two dozen other world leaders. "My visit here is to strengthen and rebuild our strategic partnership," Lula said during a meeting where he exchanged a hug with Vladimir Putin in the Kremlin. The European Union warned its members not to travel to Moscow for the event. France has been one of the most vocal supporters of Kyiv since Russia invaded Ukraine in February 2022. cf-tjc-ekf/sjw/giv
Yahoo
2 hours ago
- Yahoo
Kimberly-Clark To Sell Majority of $3.4B Global Tissue Business
Kimberly-Clark said Thursday that it agreed to create a new venture with Brazilian paper products firm Suzano. Suzano will own a 51% stake in the company's international tissue and paper products business, while Kimberly-Clark owns the remaining 49%. The Kleenex and Huggies parent said earlier this year it was looking to focus on higher growth businesses with higher profit (KMB) on Thursday announced a partnership with Brazilian pulp and paper producer Suzano (SUZ) to split ownership of Kimberly-Clark's international tissue and paper products business. The parent company of Cottonelle toilet paper and Huggies diapers said Thursday it will own a 49% stake in the business, which Kimberly-Clark named its "International Family Care and Professional" (IFP) segment in a restructuring effort earlier this year, with Suzano owning the majority 51% stake. The international tissue business Kimberly-Clark is offering up generated about $3.3 billion in sales in 2024, the company said, valuing it currently at about $3.4 billion. The IFP segment has more than 40 regional brands that the new venture will own the rights to, while five global brands like Kleenex and Scott's paper towels will be licensed to the venture, excluding Kimberly-Clark's operations in Mexico and South Korea. "Following years of deliberate investments that have strengthened Kimberly-Clark and IFP, we are excited to expand our partnership with Suzano and focus Kimberly-Clark's portfolio on our higher growth, higher margin businesses," Kimberly-Clark CEO Mike Hsu said. Suzano will later have the chance to potentially buy out Kimberly-Clark's 49% stake "at certain specified times and subject to certain conditions," the companies said. The deal announced Thursday is expected to close by the middle of next year. Kimberly-Clark's first quarter profits had topped estimates while sales fell short. When the company reported its results in April, it also lowered its full-year profit forecasts to account for the potential impact of tariffs. Shares of Kimberly-Clark were down about 2% in early trading Thursday, while Suzano's U.S.-listed shares jumped 5%. Read the original article on Investopedia
